^
    Back
    Association details:
    Biomarker:PD-L1 underexpression
    Cancer:Non Small Cell Lung Cancer
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Phase 1/2 Study to Evaluate MEDI4736

    Excerpt:
    ...Number of Participants With Best Overall Response (BOR) Assessed by BICR in NSCLC and SCCHN Cohort in the Dose-expansion Phase`Number of Participants With BOR Assessed by Investigator in the Dose-escalation, Dose-exploration, and Dose-expansion Phase`Duration of Response (DoR) Assessed by BICR in NSCLC and SCCHN Cohort in the Dose-expansion Phase`DoR Assessed by Investigator in the Dose-expansion Phase`Disease Control Rate (DCR) Assessed by BICR in NSCLC and SCCHN Cohort in the Dose-expansion Phase`DCR Assessed by Investigator in the Dose-expansion Phase`Progression-free Survival (PFS) Assessed by BICR in NSCLC Cohort in the Dose-expansion Phase`PFS Assessed by BICR in SCCHN Cohort in the Dose-expansion Phase`PFS Assessed by Investigator in the Dose-expansion Phase`OS in the Dose-Expansion Phase`ORR Assessed by BICR in UC Cohort (PD-L1 Low/Negative, Total, and PD-L1 High) in the Dose-expansion Phase`ORR Assessed by Investigator in UC Cohort (PD-L1 Low/Negative, Total, and PD-L1 High) in the Dose-expansion Phase`DoR Assessed by BICR in UC Cohort (PD-L1 Low/Negative, Total, and PD-L1 High) in the Dose-expansion Phase`DoR Assessed by Investigator in UC Cohort (PD-L1 Low/Negative, Total, and PD-L1 High) in the Dose-expansion Phase`DCR Assessed by BICR in UC Cohort (PD-L1 Low/Negative, Total, and PD-L1 High) in the Dose-expansion Phase`DCR Assessed by Investigator in UC Cohort (PD-L1 Low/Negative, Total, and PD-L1 High) in the Dose-expansion Phase`PFS Assessed by BICR in UC Cohort (PD-L1 Low/Negative, Total, and PD-L1 High) in the Dose-expansion Phase`PFS Assessed by Investigator in UC Cohort (PD-L1 Low/Negative, Total, and PD-L1 High) in the Dose-expansion Phase`OS in UC Cohort (PD-L1 Low/Negative, Total, and PD-L1 High) in the Dose-expansion Phase`Adjusted Comparison of PFS by PD-L1 Status in UC Cohort in the Dose-expansion Phase`Adjusted Comparison of OS by PD-L1 Status in UC Cohort in the Dose-expansion Phase...
    Trial ID:
    STUDY 1108
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    PD-L1 expression and progression risk of stage III NSCLC patients on durvalumab consolidation.

    Published date:
    05/28/2020
    Excerpt:
    The progression rates were 64.3%, 90.9%, and 23.1% for the PD-L1 Negative, Low PD-L1, and High PD-L1 groups respectively (Table)....While the rate of progression was higher in the Low PD-L1 group…
    DOI:
    10.1200/JCO.2020.38.15_suppl.e21070